Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 Outlook | Revenue Models

1
Alzheimers Disease Therapeutics in Major
Developed Markets to 2021 
Published on 01 February, 2016 Single
User Price 2500 No of Pages 144
The report focuses on global major leading
industry players with information such as company
profiles, product picture and specifications,
sales, market share and contact information.
Whats more, the Alzheimers Disease Therapeutics
in Major Developed Markets to 2021 development
trends and marketing channels are analyzed.
2
Summary Alzheimer's Disease (AD) is an
irreversible, progressive neurodegenerative
disease, characterized by cognitive impairment,
memory loss and functional decline. Symptoms
typically begin to first appear in patients in
their mid-sixties, with symptoms appearing in
varying stages. The pathological features of AD
comprise histopathological changes within the
brain. Mild Cognitive Impairment (MCI) is a
heterogeneous condition between normal cognition
and dementia, whereby cognitive changes in mental
abilities, such as memory or thinking, are
affected.
3
Almost all cases of AD begin with MCI, but it
should be noted that not all patients with MCI go
on to develop AD. Although there is a high degree
of failure and uncertainty within the RD of AD
drugs, the number of drugs in the pipeline is
considerably high at 559. The majority of the
pipeline products are novel drugs, with a total
of seven repositioned and five generic drugs.
This shows advancement in the progression of the
different molecules being developed as
therapeutic agents within the AD pipeline.
Click Here To Check Complete Report
4
Scope The AD market has a lack of therapeutic
options. - Which classes of drug dominate the
market? - What newly approved therapies have
entered the market? - How do the leading marketed
therapies compare clinically? - How will the new
therapies be positioned in the treatment of AD? -
How have selected late-stage pipeline therapies
performed in clinical trials? The pipeline
contains a range of molecule types and molecular
targets, including those that are well
established in AD, and novel, first-in-class
therapies. - Which molecular targets appear most
frequently in the pipeline? AD clinical trials
have an overall attrition rate of 94. - What are
the failure rates for individual Phases of
clinical development?
5

• - How do AD clinical trial characteristics,
  including failure rate, duration, and size
  compare against respiratory and industry
  averages?The AD market is forecast to rise from
  a value of 5.2 billion in 2014 to 11.3 billion
  in 2021, at a CAGR of 11.8 across the eight
  major markets assessed.- How much of a role will
  disease prevalence and new product approvals play
  in market growth?- Will generic competition have
  a significant impact on the market over the
  forecast period?There have been 170 licensing
  deals and 104 co-development deals pertaining to
  AD products since 2006.- Which territories show
  the most deal activity?- What were the trends in
  deal completion by product stage of development?

Download Sample Brochure
6
Reasons to buy This report will allow you to -
- Understand the current clinical and commercial
landscape through a comprehensive study of
disease pathogenesis, diagnosis, prognosis, and
the current treatment algorithm used in AD. -
Assess the safety and efficacy of current
treatment options, with extensive product
profiles on prominent marketed therapies, and a
heatmap directly comparing safety and efficacy
data. - Analyze the AD pipeline and stratify by
stage of development, molecule type, and
molecular target. The most promising late-stage
therapies are profiled and assessed in terms of
clinical performance and competitiveness,
alongside a single-product forecast.
7

• - Predict growth in market size in eight major
  markets, with in-depth market forecasting from
  2014 to 2021. The forecasts will provide an
  understanding of how epidemiology trends, new
  drug entries, and patent expirations will
  influence market value.
• - Identify commercial opportunities in the AD
  deals landscape by analyzing trends in licensing
  and co-development deals, and by profiling the
  most significant deals that have occurred in this
  indication in recent years.

Make an Inquiry Before Buying
8
Key questions answered in this report  What
will the market size be in 2020 and what will the
growth rate be? What are the key market
trends? What is driving this market? What are
the challenges to market growth? Who are the
key vendors in this market space? What are the
market opportunities and threats faced by the key
vendors? What are the strengths and weaknesses
of the key vendors? You can request one free
hour of our analysts time when you purchase this
market report. Details are provided within the
report.
9
Alzheimers Disease Therapeutics in Major
Developed Markets to 2021
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Alzheimers Disease Therapeutics in Major
Developed Markets to 2021 and future
opportunities are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Alzheimers Disease
Therapeutics in Major Developed Markets to 2021